Compare Abeona Therapeutics Inc (ABEO) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Direxion Daily FTSE China Bull 3x Shares trades at $28.9. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| ABEO | YINN | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $56.62 |
52-Week Low | $4.17 | $21.45 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
YINN, a leveraged ETF tracking Chinese stocks, trades at $29.01, down 10.19% amid broad bearish technical signals. Key support lies at $29, with RSI at 24.06 indicating potential oversold conditions. Recent news highlights China's AI investments and export strength, but U.S.-China tech tensions and regulatory scrutiny persist.
The outlook remains clouded by geopolitical risks and leveraged ETF decay, though oversold conditions may offer tactical opportunities. Risks include amplified volatility and policy shifts, requiring cautious positioning given the fund's structure and macro sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
